CN105288036A - Pharmaceutical composition for treating myocardial infarction and preparing method thereof - Google Patents
Pharmaceutical composition for treating myocardial infarction and preparing method thereof Download PDFInfo
- Publication number
- CN105288036A CN105288036A CN201510698652.1A CN201510698652A CN105288036A CN 105288036 A CN105288036 A CN 105288036A CN 201510698652 A CN201510698652 A CN 201510698652A CN 105288036 A CN105288036 A CN 105288036A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- fructus
- herba
- myocardial infarction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 36
- 208000010125 myocardial infarction Diseases 0.000 title claims abstract description 24
- 241001643642 Viticis Species 0.000 claims description 35
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 19
- 241000180649 Panax notoginseng Species 0.000 claims description 17
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 17
- 241000921449 Rhodobryum roseum Species 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 239000003814 drug Substances 0.000 abstract description 13
- 210000000952 spleen Anatomy 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 2
- 240000001949 Taraxacum officinale Species 0.000 abstract description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 240000005528 Arctium lappa Species 0.000 abstract 1
- 235000003130 Arctium lappa Nutrition 0.000 abstract 1
- 235000008078 Arctium minus Nutrition 0.000 abstract 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 240000006766 Cornus mas Species 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 240000006927 Foeniculum vulgare Species 0.000 abstract 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 241000921453 Rhodobryum Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 244000063464 Vitex agnus-castus Species 0.000 abstract 1
- 235000009347 chasteberry Nutrition 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000007812 deficiency Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 239000003172 expectorant agent Substances 0.000 description 7
- 230000003419 expectorant effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- 241000227129 Aconitum Species 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 241000904014 Pappus Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241001073567 Verbenaceae Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine, and relates to a pharmaceutical composition for treating myocardial infarction and a preparing method thereof. The pharmaceutical composition is prepared from, by weight, 8-15 parts of vitex, 8-15 parts of pseudo-ginseng, 6-15 parts of burdock, 3-12 parts of dandelion, 6-15 parts of fennel, 9-12 parts of Chinese yam, 6-12 parts of dogwood, 6-12 parts of cinnamon, 3-12 parts of monkshood, 6-9 parts of red rhodobryum and 1-10 parts of liquorice. The pharmaceutical composition can invigorate blood circulation, remove stasis and tonify spleen and qi and has the advantages of being good in curative effect, mild in side effect, convenient to take, easy to apply and popularize and the like.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition for the treatment of myocardial infarction and preparation method thereof.
Background technology
Myocardial infarction is the disease of the part myocardial necrosis caused due to the lasting severe ischemic of cardiac muscle, multiple be born in the middle age after, have the symptom such as the similar anginal front chest pain of violent and lasting character, cardiopalmus, asthma, weak and faint pulse, blood pressure reduction during morbidity.Primary disease incidence rate has and increases trend year by year, and arteriosclerosis accounts for 98% of Pathogenesis of Acute Myocardial Infarction rate, and patient more than 40 years old is in the majority, and many with hypertension, and nearly half is angor medical history intentionally.
In treatment, be broadly divided into two classes: one is take stopgap measures and effect a permanent cure, i.e. " symptomatic treatment in acute condition, radical treatment in chronic case "; Two is routine treatment and contrary treatment, i.e. " treating with drugs opposite to the nature of disease is called routine treatment, contrary treatment means that the remedy coincides with the pseudo-symptom of disease ", and the one that routine treatment is its syndrome character inverse and controls commonly uses therapeutic rules, and contrary treatment is a kind of Therapeutic Method of being obedient to disease illusion and controlling.The present traditional Chinese medical science thinks that the main pathogenesis of coronary heart disease myocardial infarction is deficiency in origin and excess in superficiality, and deficiency in origin is based on the deficiency of vital energy, the deficiency of YIN, and mark is real turbid common with the stagnation of QI, blood stasis, expectorant.The ancient prescription traditional Chinese medical science proposes phlegm and blood stasis theory, thinks body fluid transporting mistake department, stops poly-ly forming expectorant; Escape of blood from meridians, stays in arteries and veins outer or stagnant in arteries and veins, causes blood stasis expectorant to stop or expectorant is poly-hinders blood; Or the expectorant stasis of blood is changed mutually, stagnant in passages through which vital energy circulates to expectorant stasis blocking eventually, phlegm and blood stasis and causing a disease; And myocardial infarction be divided into type of deficiency of both QI and YIN, deficiency of YANG QI weak type, the expectorant stasis of blood to hand over three types such as resistance qi stagnation and blood stasis type, control respectively with supplementing QI and nourishing YIN, QI invigorating warming YANG, dissipating phlegm and removing blood stasis.
China applies for a patent 201410113088.8 and discloses a kind of pharmaceutical composition for the treatment of myocardial infarction, its raw materials comprises: Galla Chinensis, Flos Lonicerae, the Cortex Eucommiae, Radix Cirsii Japonici, Rhizoma Chuanxiong, Radix Rehmanniae, Periostracum Cicadae, Poria, the Radix Paeoniae Alba, Radix Codonopsis and Radix Glycyrrhizae, this pharmaceutical composition has good therapeutic effect in treatment myocardial infarction, there is significant clinical generalization value, but the effect in supplementing QI and nourishing YIN, blood circulation promoting and blood stasis dispelling etc. not very remarkable.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of pharmaceutical composition for the treatment of myocardial infarction, this pharmaceutical composition has effect of blood circulation promoting and blood stasis dispelling and invigorating the spleen and replenishing QI, also have that preparation technology is simple, good effect, side effect be low, taking convenience and be easy to advantages such as applying, in addition, the present invention also provides corresponding manufacturing process to be made and facilitate easy-to-use preparation under the prerequisite ensureing curative effect by this pharmaceutical composition.
Pharmaceutical composition of the present invention comprises the raw materials of following parts by weight: Herba Viticis Cannabifoliae 8-15 part, Radix Notoginseng 8-15 part, Fructus Arctii 6-15 part, Herba Taraxaci 3-12 part, Fructus Foeniculi 6-15 part, Rhizoma Dioscoreae 9-12 part, Fructus Corni 6-12 part, Cortex Cinnamomi 6-12 part, Radix Aconiti Lateralis Preparata 3-12 part, Rhodobryum roseum Limpr. 6-9 part and Radix Glycyrrhizae 1-10 part.
Preferably, described pharmaceutical composition comprises the raw materials of following parts by weight: Herba Viticis Cannabifoliae 6-10 part, Radix Notoginseng 8-10 part, Fructus Arctii 6-10 part, Herba Taraxaci 6-9 part, Fructus Foeniculi 6-10 part, Rhizoma Dioscoreae 9-12 part, Fructus Corni 6-10 part, Cortex Cinnamomi 6-10 part, Radix Aconiti Lateralis Preparata 5-10 part, Rhodobryum roseum Limpr. 6-9 part and Radix Glycyrrhizae 2-6 part.
Preferably, described pharmaceutical composition comprises the raw materials of following parts by weight: Herba Viticis Cannabifoliae 15 parts, Radix Notoginseng 12 parts, Fructus Arctii 12 parts, Herba Taraxaci 4 parts, 15 parts, Fructus Foeniculi, Rhizoma Dioscoreae 12 parts, Fructus Corni 12 parts, Cortex Cinnamomi 12 parts, Radix Aconiti Lateralis Preparata 10 parts, Rhodobryum roseum Limpr. 9 parts and 10 parts, Radix Glycyrrhizae.
Preferably, described pharmaceutical composition comprises the raw materials of following parts by weight: Herba Viticis Cannabifoliae 10 parts, Radix Notoginseng 6 parts, Fructus Arctii 10 parts, Herba Taraxaci 12 parts, 10 parts, Fructus Foeniculi, Rhizoma Dioscoreae 10 parts, Fructus Corni 9 parts, Cortex Cinnamomi 9 parts, Radix Aconiti Lateralis Preparata 9 parts, Rhodobryum roseum Limpr. 7 parts and 9 parts, Radix Glycyrrhizae.
Preferably, described pharmaceutical composition is made into tablet, capsule, drop pill, granule or powder.
Correspondingly, present invention also offers the preparation method of the pharmaceutical composition of described treatment myocardial infarction, comprise following step:
A) Herba Viticis Cannabifoliae is taken, be ground into coarse powder, be placed in supercritical carbon dioxide extraction apparatus, the volume fraction adding coarse powder weight 30-45% is the ethanol of 60-85%, and regulation and control carbon dioxide flow is 15-20L/h, and extracting pressure is 15-20MPa, extraction temperature is 40-60 DEG C, extraction time is 1.5-2h, and decompression separation obtains Herba Viticis Cannabifoliae extract, retains Herba Viticis Cannabifoliae residue;
B) take Radix Notoginseng, Fructus Arctii, Herba Taraxaci, Fructus Foeniculi, Rhizoma Dioscoreae, Fructus Corni, Cortex Cinnamomi, Radix Aconiti Lateralis Preparata, Rhodobryum roseum Limpr. and Radix Glycyrrhizae, add described Herba Viticis Cannabifoliae residue, pulverize, add 3-6 times amount water soaking after 1-5 hour, boil 30-60 minute, filter, obtain filtrate, 2-5 times of water gaging is added in filtering residue, boil 30-60 minute, then use slow fire boiling 1-2 hour, filter, obtain filtrate, merge twice filtrate;
C) described Herba Viticis Cannabifoliae extract and described twice filtrate are mixed, be concentrated into the thick paste that relative density is 1.20-1.35, vacuum belt type drying is carried out at 50-60 DEG C of temperature, drying pressure is-0.09MPa, charging rate is 15L/h, and material strip transfer rate is 26cm/min, is pulverized by dry extract after drying, cross 100-200 mesh sieve, to obtain final product.
Source, the nature and flavor of the present invention's component used, return through and effect:
Herba Viticis Cannabifoliae: the Herba Viticis Cannabifoliae in the present invention refers to Caulis Viticis Cannabifoliae is the stem of Verbenaceae Herba Viticis Cannabifoliae, and acrid in the mouth, micro-hardship, property are flat; Function cures mainly expelling pathogenic wind from the body surface, reducing swelling and alleviating pain.Flu, sore throat and skin ulcer are swollen etc. and has certain curative effect.
Radix Notoginseng is the dry root welding technology of panax araliaceae plant, has dissipating blood stasis hemostasis, effect of subduing swelling and relieving pain.In addition, also have comprise hemostasis, antithrombotic, promotion hemopoietic, expand blood vessel, blood pressure lowering, resist myocardial ischemia, anti-cerebral ischemia, arrhythmia, atherosclerosis, antiinflammatory, protect the liver, antitumor, the effect such as analgesia, principle active component is PNS, PDS, PTS and Radix Notoginseng propylhomoserin.
Fructus Arctii is Compositae draft taproot class plant, and be a kind of vegetable edible with loose fleshy tap root, petiole and tender leaf also edible, Fructus Arctii and Radix Arctii also can be used as medicine.The fiber of Fructus Arctii can promote intestinal peristalsis, helps defecation, reduces body inner cholesterol, and minimizing toxin, refuse accumulate in vivo, reaches prevention of stroke and the effect of preventing and treating gastric cancer, uterus carcinoma.Doctor trained in Western medicine thinks that it is except having diuresis, removing food stagnancy, eliminating the phlegm except the pharmacological actions such as stopping leak, also for the dietetic therapy of constipation, hypertension, high-cholesterol disease.The traditional Chinese medical science thinks effects such as having wind-dispelling heat-dissipating, lung qi dispersing rash, resolving toxin and disinhibiting the throat.
Dandelion Compositae herbaceos perennial.Head inflorescence, the bobbles that on seed, adularescent pappus is formed, new life is bred in the new place that racks after the flowers are in blossom.Containing multiple health-nutrition compositions such as taraxol, taraxacin, choline, organic acid, inulin in Herba Taraxaci plant, there are the effects such as diuresis, cathartic, jaundice eliminating subcutaneous ulcer, function of gallbladder promoting.Herba Taraxaci containing protein, fat, carbohydrate, trace element and vitamin etc., has abundant nutritive value simultaneously.In addition, also there is heat-clearing and toxic substances removing, effect of dispersing swelling and dissipating binds.
The main component of Fructus Foeniculi is Oleum Anisi Stellati, energy stimulating gastrointestinal neural blood vessel, and facilitating digestion liquid is secreted, and increases gastrointestinal peristalsis, gets rid of the gas accumulated, so there is effect of stomach invigorating, circulation of qi promoting; Sometimes gastrointestinal peristalsis can reduce again after excitement, thus contributes to alleviating spasm, easing the pain.Chinese medicine is used as medicine, and warm in nature, acrid in the mouth, returns liver,kidney,spleen, stomach warp.Function warming the liver kidney, warming the stomach gas, loose plug knot, dispersing cold for relieving pain, regulating qi-flowing for harmonizing stomach.Fructus Foeniculi also has antiulcer, analgesia, gonadotropic Effect etc., and Oleum Anisi Stellati has antibacterial action in various degree.Energy stimulating gastrointestinal neural blood vessel, promotes saliva and gastric secretion, plays appetite stimulator, digestive effect.Be applicable to Deficiency and coldness of spleen and stomach.
Rhizoma Dioscoreae: be the dry rhizome of Dioscoreaceae plant Rhizoma Dioscoreae; Sweet in the mouth, property is put down; Return spleen, lung, kidney channel; Spleen reinforcing nourishing the stomach, promote the production of body fluid lung benefiting, the kidney invigorating arresting seminal emission.
Fructus Corni officinalis contains abundant nutrient substance and functional component, and the experience of the Compendium of Material Medica collection ancient Chinese medicine doctor application Fructus Corni of Ming Dynasty's Li Shizhen (1518-1593 A.D.), the medicine that Fructus Corni is classified as controlling nocturnal emission with astringent drugs of enriching blood, liver and kidney tonifying, regulating QI, tonify deficiency, improving eyesight and keeps fit.
Cortex Cinnamomi is the dry bark of canella Cortex Cinnamomi; Acrid in the mouth, sweet, extremely hot in nature; Return kidney, spleen, the heart, Liver Channel; Mend fire supporing yang, let the fire back to its origin, dispersing cold for relieving pain, promoting blood circulation to restore menstrual flow.
Radix Aconiti Lateralis Preparata, has another name called Aconitum carmichjaelii Debx. or Radix Aconiti Lateralis Preparata, the processed goods of the daughter root of Ranunculaceae, aconitum plant.Function cures mainly: recuperating depleted YANG and rescuing the patient from collapse, mend fire supporing yang, dispersing cold for relieving pain.
Rhodobryum roseum Limpr. is a kind of Chinese herbal medicine, and plant body is little, the micro-hardship of taste, can as the treatment of heart disease or other mental disorder.Specially control that heart disease is nervous, cardiopalmus, the symptoms such as neurasthenia.
Radix Glycyrrhizae is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L., and Radix Glycyrrhizae contains glycyrrhizic acid, liquiritin isoreactivity composition, has the effects such as heat-clearing and toxic substances removing, invigorating the spleen and replenishing QI, expelling phlegm for arresting cough.
Compared with prior art, the present invention has following beneficial effect:
1, compared with the Chinese medicine of other treatment myocardial infarction, pharmaceutical composition of the present invention has more remarkable efficacy in blood circulation promoting and blood stasis dispelling and invigorating the spleen and replenishing QI etc.
2, compared with chemotherapeutic agent, pharmaceutical composition of the present invention is natural pure Chinese medicinal preparation, and untoward reaction significantly reduces, and pharmaceutical composition effect of the present invention is comprehensive, medication effect is better, is used for the treatment of myocardial infarction disease, has good effect, taking convenience and is easy to advantages such as applying.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following examples represents the technology playing good action in the practice of the invention of the present inventor's discovery.But, many changes can be made in disclosed specific embodiments, and still obtain same or analogous result, and not depart from the spirit and scope of the present invention.
embodiment 1
Pharmaceutical composition of the present invention is prepared from by the raw material of following parts by weight: Herba Viticis Cannabifoliae 6 parts, Radix Notoginseng 10 parts, Fructus Arctii 6 parts, Herba Taraxaci 9 parts, 6 parts, Fructus Foeniculi, Rhizoma Dioscoreae 9 parts, Fructus Corni 6 parts, Cortex Cinnamomi 6 parts, Radix Aconiti Lateralis Preparata 5 parts, Rhodobryum roseum Limpr. 6 parts and 2 parts, Radix Glycyrrhizae.
Preparation method is as follows: take Herba Viticis Cannabifoliae, be ground into coarse powder, be placed in supercritical carbon dioxide extraction apparatus, the volume fraction adding coarse powder weight 30% is the ethanol of 75%, and regulation and control carbon dioxide flow is 20L/h, and extracting pressure is 15MPa, extraction temperature is 50 DEG C, extraction time is 2h, and decompression separation obtains Herba Viticis Cannabifoliae extract, retains Herba Viticis Cannabifoliae residue; Take Radix Notoginseng, Fructus Arctii, Herba Taraxaci, Fructus Foeniculi, Rhizoma Dioscoreae, Fructus Corni, Cortex Cinnamomi, Radix Aconiti Lateralis Preparata, Rhodobryum roseum Limpr. and Radix Glycyrrhizae, add described Herba Viticis Cannabifoliae residue, pulverize, add 4 times amount water soakings after 3 hours, boil 60 minutes, filter, obtain filtrate, 2 times of water gagings are added in filtering residue, boil 60 minutes, then use slow fire boiling 1 hour, filter, obtain filtrate, merge twice filtrate; Described Herba Viticis Cannabifoliae extract and described twice filtrate are mixed, be concentrated into the thick paste that relative density is 1.25, vacuum belt type drying is carried out at 60 DEG C of temperature, drying pressure is-0.09MPa, charging rate is 15L/h, and material strip transfer rate is 26cm/min, is pulverized by dry extract after drying, cross 100 mesh sieves, obtain pharmaceutical composition.
embodiment 2:
Pharmaceutical composition of the present invention is prepared from by the raw material of following parts by weight: Herba Viticis Cannabifoliae 15 parts, Radix Notoginseng 12 parts, Fructus Arctii 12 parts, Herba Taraxaci 4 parts, 15 parts, Fructus Foeniculi, Rhizoma Dioscoreae 12 parts, Fructus Corni 12 parts, Cortex Cinnamomi 12 parts, Radix Aconiti Lateralis Preparata 10 parts, Rhodobryum roseum Limpr. 9 parts and 10 parts, Radix Glycyrrhizae.
Preparation method is as follows: take Herba Viticis Cannabifoliae, be ground into coarse powder, be placed in supercritical carbon dioxide extraction apparatus, the volume fraction adding coarse powder weight 45% is the ethanol of 70%, and regulation and control carbon dioxide flow is 15L/h, and extracting pressure is 18MPa, extraction temperature is 45 DEG C, extraction time is 2h, and decompression separation obtains Herba Viticis Cannabifoliae extract, retains Herba Viticis Cannabifoliae residue; Take Radix Notoginseng, Fructus Arctii, Herba Taraxaci, Fructus Foeniculi, Rhizoma Dioscoreae, Fructus Corni, Cortex Cinnamomi, Radix Aconiti Lateralis Preparata, Rhodobryum roseum Limpr. and Radix Glycyrrhizae, add described Herba Viticis Cannabifoliae residue, pulverize, add 5 times amount water soakings after 2 hours, boil 45 minutes, filter, obtain filtrate, 4 times of water gagings are added in filtering residue, boil 30 minutes, then use slow fire boiling 2 hours, filter, obtain filtrate, merge twice filtrate; Described Herba Viticis Cannabifoliae extract and described twice filtrate are mixed, be concentrated into the thick paste that relative density is 1.35, vacuum belt type drying is carried out at 60 DEG C of temperature, drying pressure is-0.09MPa, charging rate is 15L/h, and material strip transfer rate is 26cm/min, is pulverized by dry extract after drying, cross 100 mesh sieves, obtain pharmaceutical composition.
embodiment 3:
Pharmaceutical composition of the present invention is prepared from by the raw material of following parts by weight: Herba Viticis Cannabifoliae 15 parts, Fructus Arctii 15 parts, Radix Notoginseng 9 parts, Herba Taraxaci 12 parts, 15 parts, Fructus Foeniculi, 9 parts, Flos Carthami, Fructus Crataegi 12 parts, Fructus Corni 12 parts, Cortex Cinnamomi 12 parts, Radix Aconiti Lateralis Preparata 10 parts, Rhodobryum roseum Limpr. 9 parts and 10 parts, Radix Glycyrrhizae.
Preparation method is similar to Example 1.
clinical observation on the therapeutic effect
1, case selection: in 300 routine myocardial infarction clinical patients volunteers, male 150 example, female patient 150 example, age bracket be 40-60 year, all patients all has typical myocardial infarction clinical symptoms, and in sex, age, the course of disease no difference of science of statistics.
2, diagnostic criteria:
(1) typical myocardial ischemia symptom (chest pain or discomfort uncomfortable in chest);
(2) typical cardiac electrical figure change;
(3) Serum fibrosis markers raises.
3, efficacy assessment standard:
Cure: after drug administration, malaise symptoms disappears completely;
Effective: after drug administration, malaise symptoms alleviates or partial disappearance;
Invalid: after drug administration, malaise symptoms is unchanged;
Total effective rate=(cure+effectively)/total number of cases × 100%.
4, instructions of taking: 300 patient volunteers are divided into 3 groups at random, often organize 100 people, is respectively treatment A group, treatment B group and positive controls, treatment A group and treatment B component do not take the pharmaceutical composition that the embodiment of the present invention 1,2 prepares, every day 3 times, each 10-20g, serve on 1 month.Positive controls takes FUFANG DANSHEN DIWAN (Tianjin Tasly Pharmaceutical Co., Ltd, the accurate word Z10950111 of traditional Chinese medicines), and oral or sublingual administration, 10 balls, 3 times on the one, serve on 1 month.
5, therapeutic outcome: as shown in table 1.
table 1 therapeutic outcome
| Group | Number | Cure | Effectively | Invalid | Total effective rate |
| Treatment A group | 100 | 84 | 10 | 6 | 94％ |
| Treatment B group | 100 | 83 | 8 | 9 | 91％ |
| Positive controls | 100 | 69 | 10 | 21 | 79％ |
Compared by the therapeutic effect of pharmaceutical composition of the present invention and FUFANG DANSHEN DIWAN, the curative effect of medicine composite for curing myocardial infarction aspect of the present invention can be found out.Make inventor surprisingly, the cure rate of pharmaceutical composition of the present invention reaches more than 80%, total effective rate reaches more than 90%, far above cure rate and the total effective rate of positive controls, wherein best with the therapeutic effect for the treatment of A group, visible, the good effect of pharmaceutical composition of the present invention, cure rate is high, can be used as the drug use for the treatment of myocardial infarction.
Owing to describing the present invention by above preferred embodiment, in spirit of the present invention and/or scope, any for replacement/of the present invention or combination implement the present invention, be all apparent for a person skilled in the art, and be included among the present invention.
Claims (6)
1. treat the pharmaceutical composition of myocardial infarction for one kind, it is characterized in that, comprise the raw materials of following parts by weight: Herba Viticis Cannabifoliae 8-15 part, Radix Notoginseng 8-15 part, Fructus Arctii 6-15 part, Herba Taraxaci 3-12 part, Fructus Foeniculi 6-15 part, Rhizoma Dioscoreae 9-12 part, Fructus Corni 6-12 part, Cortex Cinnamomi 6-12 part, Radix Aconiti Lateralis Preparata 3-12 part, Rhodobryum roseum Limpr. 6-9 part and Radix Glycyrrhizae 1-10 part.
2. the pharmaceutical composition for the treatment of myocardial infarction as claimed in claim 1, it is characterized in that, comprise the raw materials of following parts by weight: Herba Viticis Cannabifoliae 6-10 part, Radix Notoginseng 8-10 part, Fructus Arctii 6-10 part, Herba Taraxaci 6-9 part, Fructus Foeniculi 6-10 part, Rhizoma Dioscoreae 9-12 part, Fructus Corni 6-10 part, Cortex Cinnamomi 6-10 part, Radix Aconiti Lateralis Preparata 5-10 part, Rhodobryum roseum Limpr. 6-9 part and Radix Glycyrrhizae 2-6 part.
3. the pharmaceutical composition for the treatment of myocardial infarction as claimed in claim 1, it is characterized in that, comprise the raw materials of following parts by weight: Herba Viticis Cannabifoliae 15 parts, Radix Notoginseng 12 parts, Fructus Arctii 12 parts, Herba Taraxaci 4 parts, 15 parts, Fructus Foeniculi, Rhizoma Dioscoreae 12 parts, Fructus Corni 12 parts, Cortex Cinnamomi 12 parts, Radix Aconiti Lateralis Preparata 10 parts, Rhodobryum roseum Limpr. 9 parts and 10 parts, Radix Glycyrrhizae.
4. the pharmaceutical composition for the treatment of myocardial infarction as claimed in claim 1, it is characterized in that, comprise the raw materials of following parts by weight: Herba Viticis Cannabifoliae 10 parts, Radix Notoginseng 6 parts, Fructus Arctii 10 parts, Herba Taraxaci 12 parts, 10 parts, Fructus Foeniculi, Rhizoma Dioscoreae 10 parts, Fructus Corni 9 parts, Cortex Cinnamomi 9 parts, Radix Aconiti Lateralis Preparata 9 parts, Rhodobryum roseum Limpr. 7 parts and 9 parts, Radix Glycyrrhizae.
5. the pharmaceutical composition of the treatment myocardial infarction according to any one of Claims 1-4, is characterized in that, described pharmaceutical composition is made into tablet, capsule, drop pill, granule or powder.
6. the preparation method of the pharmaceutical composition of the treatment myocardial infarction as described in any one of claim 1-5, is characterized in that, comprises following step:
A) Herba Viticis Cannabifoliae is taken, be ground into coarse powder, be placed in supercritical carbon dioxide extraction apparatus, the volume fraction adding coarse powder weight 30-45% is the ethanol of 60-85%, and regulation and control carbon dioxide flow is 15-20L/h, and extracting pressure is 15-20MPa, extraction temperature is 40-60 DEG C, extraction time is 1.5-2h, and decompression separation obtains Herba Viticis Cannabifoliae extract, retains Herba Viticis Cannabifoliae residue;
B) take Radix Notoginseng, Fructus Arctii, Herba Taraxaci, Fructus Foeniculi, Rhizoma Dioscoreae, Fructus Corni, Cortex Cinnamomi, Radix Aconiti Lateralis Preparata, Rhodobryum roseum Limpr. and Radix Glycyrrhizae, add described Herba Viticis Cannabifoliae residue, pulverize, add 3-6 times amount water soaking after 1-5 hour, boil 30-60 minute, filter, obtain filtrate, 2-5 times of water gaging is added in filtering residue, boil 30-60 minute, then use slow fire boiling 1-2 hour, filter, obtain filtrate, merge twice filtrate;
C) described Herba Viticis Cannabifoliae extract and described twice filtrate are mixed, be concentrated into the thick paste that relative density is 1.20-1.35, vacuum belt type drying is carried out at 50-60 DEG C of temperature, drying pressure is-0.09MPa, charging rate is 15L/h, and material strip transfer rate is 26cm/min, is pulverized by dry extract after drying, cross 100-200 mesh sieve, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510698652.1A CN105288036A (en) | 2015-09-30 | 2015-10-26 | Pharmaceutical composition for treating myocardial infarction and preparing method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015106353054 | 2015-09-30 | ||
| CN201510635305 | 2015-09-30 | ||
| CN201510698652.1A CN105288036A (en) | 2015-09-30 | 2015-10-26 | Pharmaceutical composition for treating myocardial infarction and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105288036A true CN105288036A (en) | 2016-02-03 |
Family
ID=55186314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510698652.1A Pending CN105288036A (en) | 2015-09-30 | 2015-10-26 | Pharmaceutical composition for treating myocardial infarction and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105288036A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772775A (en) * | 2012-08-02 | 2012-11-14 | 李承平 | Tablet for returning Yang and tonifying Qi |
-
2015
- 2015-10-26 CN CN201510698652.1A patent/CN105288036A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772775A (en) * | 2012-08-02 | 2012-11-14 | 李承平 | Tablet for returning Yang and tonifying Qi |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107029146B (en) | Traditional Chinese medicine composition for clearing lung, eliminating phlegm, tonifying qi, invigorating spleen and nourishing lung and preparation method thereof | |
| CN104958646A (en) | Chinese medicinal preparation for relaxing bowels and preparation method thereof | |
| CN103784918A (en) | Medicine composition for treating regurgitation-induced quidding of equus animals | |
| CN104940597A (en) | Chinese herbal composition used for treating myocardial infarction, and preparation method of Chinese herbal composition | |
| CN113209194B (en) | Composition for treating chronic gastritis and preparation method and application thereof | |
| CN108653432B (en) | Traditional Chinese medicine composition and preparation thereof | |
| CN105232677A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method of traditional Chinese medicine composition | |
| CN104042981A (en) | Medicament for treating postnatal constipation and preparation method thereof | |
| CN108888735B (en) | A kind of traditional Chinese medicine composition for treating chronic constipation | |
| CN103495103B (en) | Medicament for promoting digestion and strengthening spleen | |
| CN113332390A (en) | Traditional Chinese medicine composition for tonifying liver and kidney and preparation method thereof | |
| CN105770673A (en) | Application of Chinese herba preparation containing folium artemisiae argyi in preparing drug for treating chronic gastritis | |
| CN104524535A (en) | Traditional Chinese medicine composition for treating chronic pulmonary heart disease and preparation method of traditional Chinese medicine composition | |
| CN105396019A (en) | Pharmaceutical composition for relieving radiotherapy reaction of tumor patients | |
| CN105288036A (en) | Pharmaceutical composition for treating myocardial infarction and preparing method thereof | |
| CN107519261A (en) | A kind of Chinese medicine composition for treating leukaemia and preparation method thereof | |
| CN105770760A (en) | Preparation for treating gastric ulcer and preparation method thereof | |
| CN105687656A (en) | Pharmaceutical composition for treating myelitis and preparation method thereof | |
| CN103656199A (en) | Traditional Chinese medicine for treating cough caused by kidney Yin deficiency | |
| CN103623271B (en) | A kind of preparation method of eight-ingredient stomach-regulating oral formulations | |
| CN104757570A (en) | Herbal cuisine releasing hepatorenal function damage caused by radiation treatment and preparation method | |
| CN104666468A (en) | Pharmaceutical composition for treating hyperthyroidism and scrofula | |
| CN120078871A (en) | Traditional Chinese medicine composition for treating chronic diarrhea and application thereof | |
| CN103495069A (en) | Pharmaceutical composition for treating postpartum neurosis intestinal obstruction | |
| CN108452230A (en) | A kind of composition and preparation method thereof of tranquilization and refreshment intelligence development |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |